Glioblastoma trials in China

In China 58 Also abroad 424

58 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase I Clinical Study of YN003 in the Treatment of Glioma
Where
Beijing
Age
18 years to 70 years
People
50 worldwide
Run by
Beijing Inno Medicine Co., Ltd.
See details and how to joinNCT07929909
Phase 1/2Not yet taking people in China
DLL3 CAR-T Therapy Targeting Brain Tumors
Where
Shenzhen
Age
2 years to 70 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT07180927
Phase 1Not yet taking people in China
Immune Modulatory DC Vaccine Against Brain Tumor
Where
Shenzhen
Age
1 year to 75 years
People
10
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03914768
Phase 1/2Taking people
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Where
Beijing, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shenzhen, Xi’an, Zhuhai
Age
18 years to 70 years
People
42
Run by
Guangzhou Virotech Pharmaceutical Co., Ltd.
See details and how to joinNCT07093814
Phase 1/2Taking people
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Where
Beijing, Hangzhou, Nanjing, Wuhan
Age
18 years and over
People
450 worldwide
Run by
Bayer
See details and how to joinNCT06914128 · EU 2025-520623-24-00
Phase 2Taking people
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Where
Beijing, Chongqing, Jinan, Shanghai, Shenzhen, Wuhan
Age
18 years to 75 years
People
75
Run by
BioNTech SE
See details and how to joinNCT07297212
Phase 3Taking people
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Where
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Shanghai
Age
18 years and over
People
365 worldwide
Run by
Nuvation Bio Inc.
See details and how to joinNCT05303519
Phase 2/3Not yet taking people in China
Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
Where
Beijing
Age
18 years to 65 years
People
60
Run by
Beijing Tiantan Hospital
See details and how to joinNCT07873996
Phase 1/2Not yet taking people in China
Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence
Where
Wenzhou
Age
18 years and over
People
96
Run by
First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT07831187
Phase 2Not yet taking people in China
Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma
Where
Tianjin
Age
18 years to 69 years
People
140
Run by
Tianjin Medical University General Hospital
See details and how to joinNCT07758062
Phase 1/2Taking people
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Where
Shanghai
Age
18 years and over
People
40
Run by
Jecho Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07501559
Phase 1Taking people
A Study of DEG6498 in Participants With Solid Tumors
Where
Beijing, Guangzhou
Age
18 years and over
People
100
Run by
Degron Therapeutics Co.
See details and how to joinNCT07244835
Phase 2Taking people
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression
Where
Hangzhou
Age
18 years and over
People
31
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07670026
Early phase 1Taking people
[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
Where
Beijing
Age
18 years and over
People
24
Run by
Beijing Tiantan Hospital
See details and how to joinNCT07655869
Early phase 1Taking people
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
Where
Beijing
Age
18 years to 80 years
People
5
Run by
Beijing Tiantan Hospital
See details and how to joinNCT07648823
No phaseTaking people
Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
Where
Changsha
People
500
Run by
Xiangya Hospital of Central South University
See details and how to joinNCT07608003
No phaseTaking people
NK Cell Therapy for Malignant Solid Brain Tumors
Where
Beijing, Qinhuangdao, Zhengzhou
Age
18 years to 70 years
People
27
Run by
Peking University Third Hospital
See details and how to joinNCT07552233
No phaseTaking people
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
Where
Wuhan
Age
18 years and over
People
26
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07552467
Phase 1Taking people
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Where
Shenzhen
Age
18 years to 75 years
People
36
Run by
Beijing Biotech
See details and how to joinNCT07551336
Early phase 1Taking people
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
Where
Shanghai
Age
18 years and over
People
10
Run by
Huashan Hospital
See details and how to joinNCT07538128
Phase 1/2Taking people
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Where
Shenzhen
Age
18 years to 75 years
People
72
Run by
Beijing Biotech
See details and how to joinNCT07523529
Early phase 1Enrolling by invitation
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
Where
Beijing
Age
18 years and over
People
9
Run by
Beijing Neurosurgical Institute
See details and how to joinNCT07520214
Phase 2Taking people
Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma
Where
Hangzhou
Age
18 years to 75 years
People
38
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07511725
Phase 1Taking people
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Where
Shenzhen
Age
18 years to 75 years
People
36
Run by
Beijing Biotech
See details and how to joinNCT07480941
Phase 1Not yet taking people in China
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
Where
Guangzhou
Age
18 years to 70 years
People
40
Run by
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
See details and how to joinNCT07455045